|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Epigenomics AG And Academic Partners Receive BMBF Grant To Develop Novel Techniques For Early Cancer Detection Based On DNA-Methylation
10/19/2005 5:11:04 PM
Epigenomics AG today announced the receipt of BMBF (German Ministry for Education and Research) funding for a three-year project to design and develop new techniques for high-throughput early cancer screening based on DNA methylation, a natural “switch” that controls gene expression.
The BMBF, through its BioChance Plus programme, will contribute €1.1 million of the estimated €2.7 million project total. The project will be conducted in collaboration with the teams of Prof. Albert Jeltsch, International University of Bremen (IUB) and Prof. Jörn Walter, a co-founder of Epigenomics and now at the Universität des Saarlandes, two leading academic groups involved in the DNA methylation field. The award was presented yesterday by Secretary of State Christoph Matschie to Kurt Berlin, PhD, Chief Scientific Officer of Epigenomics, during the opening of the BMBF Biotechnology Days 2004 that are currently held in Jena, Germany.
|
|
|
|
|
|
|
|
|
|
|